| Z03905 | |
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 71.6 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. | ||||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | Her3, also called ErbB3, is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. Her3 is expressed in keratinocytes, melanocytes, skeletal muscle cells, embryonic myoblasts and Schwann cells. Monomeric Her3 serves as a low affinity receptor for the heregulins (HRG). |
| Synonyms | ErbB3; ErbB-3; HER3; HER3c-erbB-3; LCCS2; MDA-BF-1; MGC88033; p180-ErbB3; p45-sErbB3; p85-sErbB3; ERBB3 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
